Q2028 – Injection, sculptra, 0.5 mg

Long description

Injection, sculptra, 0.5 mg

Short description

Inj, sculptra, 0.5mg

Pricing indicator

51 Drugs

Medicare coverage

D Special coverage instructions apply

BETOS category

O1E Other drugs

ASC

Approved for ambulatory surgical centers

Added

January 1, 2014

Last change

January 1, 2019 – No change

Nearby Q codes

• Q0520 – Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription injectable drug, per 60-days
• Q0521 – Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription
• Q1004 – New technology intraocular lens category 4 as defined in federal register notice
• Q1005 – New technology intraocular lens category 5 as defined in federal register notice
• Q2004 – Irrigation solution for treatment of bladder calculi, for example renacidin, per 500 ml
• Q2009 – Injection, fosphenytoin, 50 mg phenytoin equivalent
• Q2017 – Injection, teniposide, 50 mg
• Q2026 – Injection, radiesse, 0.1 ml
• Q2034 – Influenza virus vaccine, split virus, for intramuscular use (agriflu)
• Q2035 – Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria)
• Q2036 – Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval)
• Q2037 – Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin)
• Q2038 – Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone)
• Q2039 – Influenza virus vaccine, not otherwise specified
• Q2040 – Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
• Q2041 – Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose